Metropolis Healthcare has achieved a revenue growth of 40% Year on Year (YoY) in Q4FY21 as compared to Q4FY20. Non-Covid Business revenue increased by 21% YoY in Q4FY21 as compared to Q4FY20. Inspite of conducting higher Covid Tests on QoQ basis, Covid Business revenue (RT-PCR Tests) stood at 14% of total revenue in Q4FY21 as compared to 19% in Q3FY21 due to reduction in Test prices by Government agencies.
The Company recorded highest ever monthly revenue in March 2021 on the back of strong growth in Non-covid business coupled with an uptick in covid business.
Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
Trending Stocks
Recommended Articles